LYPLA2P3

Across TCGA pan-cancer cohorts, LYPLA2P3 RNA is linked to patient survival in 6 of 34 cancer types, making it the most broadly survival-associated LYPLA2P3 data layer.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher LYPLA2P3 RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated LYPLA2P3 expression acts as an unfavorable survival marker, although some lineages such as KIRC show a favorable association.

KIRC, PAAD, and TGCT are the cancer types where LYPLA2P3 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Median	All	0.737	0.574	.001	103	view →
PAAD	OS	Tertile	All	0.100	0.614	<.001	72	view →
TGCT	OS	Tertile	III,IV	0.003	1.000	<.001	60	view →
READ	DFS	Tertile	III,IV	0.174	0.747	.005	18	view →
STAD	DFS	Tertile	IV	0.097	0.483	.031	15	view →
HNSC	OS	Tertile	II,III,IV	0.468	0.680	.033	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LYPLA2P3–KIRC (DFS)

Open the KIRC breakdown →